+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025

  • ID: 5359672
  • Report
  • May 2021
  • Region: China
  • 144 Pages
  • AEI Research


  • Peijia Medical
  • Venus Medtech
Heart valve disease belongs to structural heart disease, which has great influence on patients' quality of life. If patients with moderate or severe valvular disease are not treated, their 5-year survival rate is only 20%. According to the characteristics of the heart valve industry in China, there are a large number of patients with valvular diseases in China, but most of the treatment needs have not been met, and the operations are mainly concentrated in large head hospitals. More importantly, the population structure of patients with valvular disease in China is not consistent with that in Europe and America. There are many patients with rheumatic heart disease in history, and the age of first treatment is 30-40 years old, which is far lower than that in Europe and America, resulting in a large amount of mechanical valves used in China. Now, with the accumulation of durability data of surgical bioprosthetic valve and the gradual change of patient population structure in China, this situation is changing. From the perspective of industry development, there are already many domestic enterprises in the valve field. With the listing of Edward's interventional valve SAPIEN3 in China in 2020, we believe that China's valve industry is at the development base, and the market space needs to be opened urgently.

In 2019, the global market for heart valves is close to US$ 6 billion, of which TAVR exceeds US$ 4 billion and surgical valves is about US$ 1.8 billion. We estimate that the total market in China is about RMB 2 billion. Surgical valve is still the basic demand of valve replacement market in China, and domestic biological surgical valve will benefit from the replacement of mechanical valve and imported valve. At present, the domestic TAVR base is extremely low, which will become the biggest growth point with the continuous listing and academic promotion of products. TMVR technology is still immature, but the patient population is 5~10 times that of TAVR, which is the direction of industry R&D layout.

According to the characteristics of the valve industry in China, we believe that the domestic valve industry may have the following development trends:
  • Biological valves will gradually replace mechanical valves;
  • Domestic bioprosthetic valve has a large import substitution space;
  • Interventional surgery and surgery will complement each other for a long time, which is mainly determined by clinical needs. At present, interventional surgery can only treat patients with aortic valve diseases, with a larger proportion of patients with mitral and tricuspid valves. There is no mature interventional replacement scheme in the world. Therefore, it is expected that interventional surgery and surgery will complement each other for a long time to come.
  • In the way of interventional operation, we think that spherical expansion valve may have more advantages than self-expansion valve. Spherical expansion valve has greater radial support and shorter structure, lower clinical risk and better effect, and may have more advantages in clinical use.
  • In the long run, valve durability is still the core. We believe that the key to measure a valve is not whether it can be used, but whether it can be used more durably, whether it is an interventional valve or a surgical valve. Because the heart is the most complex organ of human body, it is difficult to change the valve frequently, so whether the valve can be used for a long time is the most important factor to measure whether a valve is a good product. Edward fully proved the durability of his valve through his unique anti-calcification technology and long-term large-scale return visit data, and gradually became the leader of the global valve industry.
Note: Product cover images may vary from those shown


  • Peijia Medical
  • Venus Medtech
1 General Overview

2 Overview of the market of artificial heart valve industry in China
2.1 definition and classification of artificial heart valve
2.2 the development process of China's artificial heart valve industry
2.3 market size of artificial heart valve industry in China
2.4 China's artificial heart valve industry chain analysis
2.4.1 upstream analysis
2.4.2 downstream analysis

3 analysis of driving factors of artificial heart valve industry in China
3.1 Population aging drives demand growth
3.2 Biomedical materials help industry development
3.3 New technology reduces the difficulty of implantation

4 Analysis of restrictive factors of artificial heart valve industry in China
4.1 Price control risks affect industry profits
4.2 High surgical risk hinders the improvement of surgical permeability
4.3 High-durability products impact the Chinese product market

5. Policy analysis of China's artificial heart valve industry

6 Analysis of the development trend of artificial heart valve industry in China
6.1 Biological valve and interventional technology are important trends in the development of the industry
6.2 Develop independent intellectual property rights

7 Analysis on the competitive pattern of artificial heart valve industry in China

Selected Charts
Figure 1: Schematic diagram of normal and diseased heart valves
Figure 2: Comparison of survival rates of various diseases
Figure 3: Number of patients with heart valve diseases in China
Figure 4: Number and proportion of aging population over the years
Figure 5: Incidence of heart valve diseases at different ages
Figure 6: The proportion of classified cardiovascular diseases in China in 2017
Figure 7: Heart valve replacement in the United States in 2018 and speculated domestic market space
Figure 8: Treatment diagram of minimally invasive and interventional operation of heart valve
Figure 9: The top ten hospitals in terms of cardiac surgery in 2019
Figure 10: Distribution of cardiac surgery volume in three major hospitals in China in 2019
Figure 11: Etiological distribution of common valvular heart diseases in China in 2016
Figure 12: Classification of artificial heart valve products
Figure 13: Usage of aortic valve replacement surgery in Europe in 2012 and 2017
Figure 14: Current usage ratio of mechanical valve and biological valve in China
Figure 15: Etiological composition of valvular heart disease treated in Fuwai Hospital over the years
Figure 16: Age development trend of patients undergoing valve surgery in China
Figure 17: Current market competition pattern of surgical bioprosthetic valve in China
Figure 18: Incidence of valvular heart disease in the elderly
Figure 19: Net sales of heart valve intervention and surgery in Edward, USA, 2015-2019
Figure 20: The proportion of interventional valves and surgical valves in Edward valve sales in 2019
Figure 21: The number of heart valve operations in sample hospitals from 2013 to 2019
Figure 22: Structure and input mode of spherical expansion flap (upper) and self-expansion flap (lower)
Figure 23: RF distribution of several interventional valves with different diameters
Figure 24: Comparison of the related situation of patients with valvular disease after implantation through spherical expansion and self-expansion interventional system
Figure 25: Development history of biological valve industry
Figure 26: Material and host factors are the core factors that determine the durability of implanted materials
Figure 27: covalent crosslinking between protein
Figure 28: Glutaraldehyde (rightmost) can achieve flexible covalent crosslinking between protein
Figure 29: Edward's third generation crosslinking technology based on glutaraldehyde
Figure 30: A series of long-term cohort studies proved the durability of Edward's bovine pericardial valve
Figure 32: Comparison of hemodynamic performance between bovine pericardial valve and porcine aortic valve from 11 studies from 2000 to 2013
Note: Product cover images may vary from those shown
  • Venus Medtech
  • Peijia Medical
  • MicroPort CardioFlow Medtech Corporation
  • Suzhou Jiecheng Medical Technology Co., Ltd.
  • Beijing Balance Medical Technology Co.,Ltd
Note: Product cover images may vary from those shown